Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Eton Pharmaceuticals, Inc. reported revenue of $80M, up 104.9% year over year. Operating margin was -1.1% and net margin -5.8%, on a free-cash-flow margin of 12.7% with capital expenditure at 0.4% of revenue. Every figure is computed directly from ETON's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $80M | -1.1% | -5.8% |
| FY2024 | $39M | -6.7% | -9.8% |
| FY2023 | $32M | -3.8% | -3.0% |
| FY2022 | $21M | -38.9% | -42.4% |
| FY2021 | $22M | -6.8% | -9.0% |
How does ETON compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.